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A randomised controlled pilot study investigating the effect of 
increasing physical activity and/or omega-3 supplementation 
on fatigue in patients with inflammatory bowel disease 
Short title/Running head: Lifestyle changes in IBD-related fatigue 
 
ABSTRACT  
Objective: Fatigue is frequently reported by patients with inflammatory bowel disease 
(IBD), irrespective of disease activity; however, evidence regarding fatigue 
management is limited. This study tested the effect of individualised advice to increase 
physical activity and/or omega-3 fatty acids supplementation on fatigue in inactive IBD.  
Methods: Patients in remission were recruited to a pilot study  utilising a randomised 
controlled 2x2 factorial design (four groups) comparing baseline and post-intervention 
fatigue scores. Study interventions (12 weeks): individualised exercise advice (15-
minute consultation) and/or supplementation (omega-3 fatty acids, 2970mg/day). 
Control interventions: general health discussion and/or placebo supplement. Primary 
outcome was fatigue measured by Functional Assessment of Chronic Illness Therapy-
Fatigue (FACIT-F) scale score; secondary outcomes included change in Inflammatory 
Bowel Disease-Fatigue (IBD-F) scale score. 
Results: From n=656 screened patients, n=74 who met the eligibility  criteria  (designed 
to remove confounding factors)  were randomised, n=60 commenced,  and n=52 
completed the study. The primary outcome, fatigue measured with FACIT-F score, was 
worse with omega-3 supplementation (95%CI:-8.6-(-0.7);p=0.02), and unchanged with 
exercise advice (p=0.38). Fatigue, measured by IBD-F score, was reduced with exercise 
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advice (95%CI:-3.8-(-0.2);p=0.03). One treatment-related adverse event 
(musculoskeletal pain) was reported with exercise. 
Conclusions: Advice to increase physical activity and omega-3 supplementation, singly 
or in combination, were shown to be well-tolerated in IBD patients in remission. There 
was no evidence of exercise-related adverse effects on gut symptoms. Fatigue (IBD-F 
score) was reduced with exercise advice,  but fatigue (FACIT-F score) was unchanged. 
Increasing fatigue with omega-3 supplementation is unexplained. Regular exercise may 
be a self-management option in IBD-related fatigue. 
Keywords: IBD-Fatigue; Nutrition; Omega-3 supplementation; Physical Activity. 
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INTRODUCTION 
Fatigue is a predominant feature of inflammatory bowel disease (IBD), irrespective of 
disease activity[1]. While high fatigue prevalence (86%) is observed in active disease 
(characterised by symptoms including diarrhoea; abdominal pain, cramping and 
bloating;  fever), fatigue levels are still high (41-48%) in disease remission (periods of 
asymptomatic inactive disease)[1]. Fatigue is reported as a major concern for IBD 
patients[2, 3], with negative impact on health-related quality of life (HRQOL)[4]. Several 
physical and psychological factors, such as disease activity and depression, have been 
suggested to influence IBD-related fatigue, although inconsistencies in these reports 
prevent firm conclusions being drawn[1, 5]. Results from randomised controlled trials 
(RCTs) on IBD-related fatigue have reported reductions of fatigue with infliximab or 
adalimumab[6, 7, 8], and benefits from a stress management programme[9] and 
solution-focused therapy[10]. However, few studies identify fatigue as their primary 
endpoint[11], or compare fatigue occurring in the two types of IBD (Crohn’s Disease 
[CD] and Ulcerative Colitis [UC]); in addition, the management of fatigue in remission 
has received limited attention, despite the fact that focusing specifically on the inactive 
disease phase allows investigation of IBD-related fatigue unrelated to gut symptoms. 
This pilot RCT aimed to test the effectiveness and acceptability of two interventions (i) 
individual advice to increase PA and/or (ii) supplementation with ω-3 FAs, on fatigue in 
patients with inactive IBD. 
Fatigue features in diseases involving the immune system, e.g. cancer, rheumatoid 
arthritis, and multiple sclerosis. Recent evidence suggests similarities in fatigue 
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between  different conditions[12, 13], though it is unclear which elements of fatigue 
co-exist.  Although physical activity (PA) has been suggested to be appropriate for 
adults and children with IBD[14, 15], patients may raise concerns regarding exercise-
related exacerbation of their symptoms [16]. 
A few small cohort studies testing PA in IBD patients have reported exercise to be well-
tolerated[17, 18, 19, 20]. Low intensity exercise (cycling) was tolerated in patients with 
CD [17]; improvements in HRQOL and psychological benefits were reported in CD 
patients (with no/mild-moderate disease activity) undergoing low-moderate intensity 
PA programmes[16, 18, 19, 20, 21]. Greater impairments in physical fitness (assessed 
by cardiorespiratory fitness, 6-minute walk distance, and isokinetic muscle strength) 
and PA levels were reported in fatigued compared with non-fatigued IBD patients, and 
these were ameliorated by exercise[22]. Self-reported fatigue and skeletal muscle 
fatigue were significantly correlated in CD patients and non-IBD controls[23]. It has 
been suggested that anti-inflammatory peptides released by exercising muscle could 
reduce muscle fatigue[24]. This mechanism may have potential for reducing IBD-
related fatigue.  
Omega-3 fatty acids (ω-3 FAs, also known as omega-3 fish oils) are polyunsaturated 
fatty acids essential for normal physiological function in humans, and include the long-
chain ω-3 FAs,  eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).  
 Several characteristics of ω-3 FAs suggest a potential beneficial role in the 
management of IBD-related fatigue, with positive effects on muscle strength and/or 
reduced muscle fatigue[25], decreased inflammation and improved mood[26]. EPA  
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was reported to be particularly beneficial for treating mild depression[27], suggesting 
that ω-3 FAs might improve mood and HRQOL in IBD patients through the release of 
cytokines, neuropeptides and eicosanoids in the gut, hence influencing brain 
function[28, 29].  
Given there are no evidence-based guidelines or recommendations regarding type, 
duration and intensity of exercise for IBD patients[30], we selected an individualised  
‘Treat-to-Target’ strategy for the exercise advice intervention, aiming to initiate a ≥30% 
increase in PA levels[31]. The regime for the ω-3 FA intervention was comparable  with 
the dose and frequency of regimes used in studies on the effect of ω-3 FA on IBD 
disease activity [1, 32]. 
METHODS  
A pilot RCT with a 2x2 factorial design was used to test the effect of PA and/or ω-3 FAs 
on fatigue. The active interventions consisted of: i) Personalised exercise advice to 
increase PA by 30% and ii) Oral ω-3 FA capsule supplementation. Participants were 
randomised to one of four groups (See Table I): 
1) Exercise advice with ω-3 FAs supplement capsule 
2) Exercise advice with placebo capsule  
3) ω-3 FAs supplement capsule with exercise placebo  
4) Placebo capsule with exercise placebo  
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Researchers were blinded to capsule type, but not to consultation type; participants 
were blinded to capsule type and objective PA accelerometer readout, but not to their 
own level of PA. Block randomisation with computer-generated random numbers 
allotted participants to one of the four study groups at the first appointment, ensuring 
similar characteristics and number of participants per group. A schedule of three visits, 
baseline measures, initiation, and completion of the intervention, were required for 
participation in the study (see Figure 1 and Supplementary Data, Methods).  All patients 
received follow-up support via email or telephone. The study was approved by the 
Dulwich Research Ethics Committee (REC 12/LO/1856;13/12/2012). All data were 
coded prior to analysis to ensure participants’ confidentiality and anonymity.  
Study Participants 
Prospective study participants were approached at tertiary referral hospital IBD out-
patient clinics. Those willing to participate were recruited if they met the eligibility 
criteria of: clinically confirmed CD or ulcerative colitis in remission [C-reactive protein 
(CRP) <5mg/dl; Harvey-Bradshaw Index (HBI) <5 [33] or Simple Clinical Colitis Index 
(SCCI) <3 [34]]; self-diagnosed fatigue; ≥18 years old; willing to increase their current 
activity levels; and able to take medication with ingredients derived from animal/fish 
sources.  
Patients were excluded if they had any comorbidities likely to be confounders for 
fatigue: anaemia, depression, multiple sclerosis, unstable respiratory or cardiovascular 
disease, uncontrolled hypertension, mental illness, cognitive dysfunction, reduced 
mobility,  Chronic Fatigue Syndrome or Myalgic Encephalopathy. Patients were also 
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excluded if they were currently pregnant, taking anticoagulant medications, consumed 
oily fish ≥ twice per week or 8 times per month, took ω-3 FA supplements during the 
12 weeks before screening, performed ≥60 minutes of moderate to vigorous exercise 
weekly, or were currently participating in another RCT.  
Description of interventions 
Interventions were delivered over a 12 week period.  
i) Exercise Advice: An individual 15-minute consultation with a personal trainer and 
researcher (AM) was provided at week 1. Advice consisted of personalised goal setting 
using the treatment paradigm of ‘Treat-to-Target’ to initiate a ≥30% increase in PA 
levels[31]. This is in line with current recommendations of 30-60 min of dynamic 
exercise of the large muscles, three to four times per week [35]. Personal PA goals and 
achievements were recorded in a diary kept by participants for the study duration.  A 
positive approach to the PA advice provided was encouraged by initiating and 
maintaining motivation. This utilised techniques of imagery, goal setting (for each week 
and the whole programme), and overcoming barriers to exercise (e.g. physical 
limitations and fears of worsening IBD symptoms). The exercise trainer assessed 
participants’ mobility, and from their self-reported clinical and exercise history 
(frequency, duration and intensity of exercise), suggested a type of activity enabling an 
increase in exercise levels. Examples of PA for less active individuals included initiation 
of walking, swimming and simple gym routines. For those already undertaking some 
exercise, the trainer suggested activities enabling them to extend their personal goals, 
e.g. training for a 5km - 10km run.  
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ii) ω-3 FA Supplement Capsules: A total daily oral dose comprised 2970mg 
pharmaceutical grade ω-3 FAs (EPA, 2250mg; DHA, 150mg; “Take Omega-3”©, 
Edinburgh, UK) in three capsules. Current guidelines suggest that doses up to 3g per 
day of marine derived ω-3 FAs are safe [36]; a high EPA:DHA ratio is thought to be 
preferable [27, 37, 38].   
iii) Exercise Placebo: A 15-minute conversation with the researcher (AM) about the 
participant’s’ current dietary habits and general health was undertaken at week 1, 
including questions such as: ‘Can you tell me about your current diet?’, ‘Did you have 
to change your diet following the diagnosis of IBD?’, and ‘In what way has IBD affected 
your general health?’ No advice was given by the researcher regarding exercise. 
iv) Placebo Capsule: Similar appearing capsules to the ω-3 FA supplement capsules 
contained placebo (capric and caprylic acid).  
Participants in all groups were contacted by the researcher (AM) via telephone or email 
on six occasions during the intervention, a week following commencement of the 
interventions and then approximately every two weeks. Topics of conversation covered 
their well-being, whether they were taking the capsules as instructed, and the 
occurrence of any adverse effects. In addition, those receiving exercise advice were 
asked about progress towards set goals during that period. The exercise goals were 
reinforced and renegotiated (if necessary), and any adverse effects or barriers to 
activity were discussed. Participants were also reminded not to eat ≥2 portions of oily 
fish/week or 8 portions per month, and not to take additional ω-3 FA supplements 
during the intervention period. 
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Compliance to ω-3 FA supplement intake was assessed via self-report diary, kept by all 
study participants, in which they recorded their capsule intake, levels of dietary sources 
of ω-3 FAs, and possible treatment-related adverse effects. Participants returned left-
over capsules, which were counted to assess the number of capsules missed. 
Compliance to increased exercise during the intervention period was assessed by 
comparison of goals set and achievements recorded in the self-report diaries.  
Study Outcomes and Measurement Tools 
The primary study outcome was fatigue, measured with the Functional Assessment of 
Chronic Illness Therapy – Fatigue scale (FACIT-F)[39]. Other fatigue scales were used as 
secondary outcome measures: the Multidimensional Fatigue Inventory (MFI)[40] and 
the Inflammatory Bowel Disease-Fatigue (IBD-F) scale [41]. The rationale for using 
these different scales is provided in Table II. In addition, HRQOL was assessed with the 
Inflammatory Bowel Disease Quality of Life questionnaire (IBDQ)[42], and anxiety and 
depression with the Hospital Anxiety and Depression Scale (HADS)[43]. Physical activity 
levels were recorded daily for up to seven non-contiguous days (incorporating two 
weekend days and at least four weekdays), using a bi-axial accelerometer GT1M 
(Actigraph, Pensacola, US)[44]. A valid PA assessment was defined as wear-time ≥11 
hours per day, and data were analysed using Actilife data analysis software version 6.5. 
All outcomes were assessed at baseline and at the end of the treatment. Participants’ 
demographic data and other variables (see Table II) were also collected. 
Statistical Methods 
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Categorical variables were analysed with Fisher's exact test.  Normally distributed 
continuous variables were analysed using analysis of variance (ANOVA), whilst the 
Kruskal-Wallis test was used for non-normally distributed continuous variables. 
Continuous outcomes were analysed using analysis of covariance (ANCOVA), with a log 
scale used for non-normally distributed data. Binary outcomes were analysed by 
logistic regression. The baseline value of each outcome was used as a covariate in the 
analysis. A p-value ≤0.01 was deemed statistically significant for all outcomes since 
multiple measurements were collected. 
RESULTS  
Study Participants 
Recruitment took place over a period of 13 months, and 656 patients with confirmed 
or suspected IBD were screened. Seventy-four eligible participants received the Patient 
Information Sheet before informed consent was obtained, 60 were randomised and 
commenced the intervention, and 52 completed the protocol. Study flow, and reasons 
for exclusion and withdrawal of participants are shown in Figure 2.  
Data were analysed on an intention-to-treat basis; however, results did not differ from 
those following per protocol analysis. 
Baseline variables 
Patient demographics and baseline values of variables in the four study groups were 
comparable in relation to disease type, location, activity scores, treatment received 
(Table III), and scores for fatigue scales, Health-Related Quality of Life, and PA 
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(Supplementary data, Table SI). The only difference between groups at baseline was for 
depression (p=0.04), highest in the group receiving ω-3 FAs and exercise placebo, which 
was adjusted for in subsequent analyses. 
Outcome variables 
There were no interactions (at p-value <0.01) between the effects of exercise advice 
and those of ω-3 FAs on fatigue (Table IV). In this circumstance, the 2x2 factorial study 
design enables analysis as two rather than four groups. Hence, fatigue levels could be 
compared for participants receiving exercise advice (n=26) versus exercise placebo 
(n=26) (regardless of whether they took ω-3 FAs); and fatigue levels could be compared 
for participants receiving ω-3 FA supplement (n=25) versus placebo supplement (n=27) 
(regardless of whether they had received exercise advice), adjusted for the baseline 
difference in depression between groups (Table I).  
There was no significant difference in fatigue measured by FACIT-F score between 
those receiving exercise advice and exercise placebo (p=0.38). However, a small but 
statistically insignificant difference was shown between mean FACIT-F scores for those 
receiving the ω-3 FA supplement compared to those receiving placebo capsules (mean 
(95% CI):-4.6(-8.6,-0.7);p=0.02): Patients receiving ω-3 FA supplements had average 
scores 4.6 units lower (worse fatigue) than patients receiving placebo.  
Fatigue severity, measured by the IBD-F scale as a secondary outcome, was lower in 
patients receiving exercise advice than in those receiving exercise placebo (mean (95% 
CI):-2.0(-3.8,-0.2);p=0.03). However, there was no observed effect of ω-3 FAs on the 
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IBD-F scale scores (Table IV). No statistically significant changes for any of the other 
secondary outcomes (disease activity scores, other fatigue scale scores, and anxiety 
and depression scores) were found between exercise advice, ω-3 FAs, or placebo 
groups (at p-value <0.01) (Table IV). 
Satisfactory compliance of all groups to low levels of dietary sources of ω-3 FAs, and 
correct capsule intake were reported (Table IV). Diary entries from the exercise groups 
indicated broad compliance with the goals set, although no changes in PA levels were 
documented following the intervention period (Table IV). 
Adverse events 
There were no differences in the number of adverse events (gastrointestinal, 
musculoskeletal, and dermatological) reported between the four treatment groups 
(Figure 3), indicating that the adverse effects reported were unlikely to be linked to the 
interventions. The Odds Ratios (CI 95%) for a patient experiencing an adverse event 
following receipt of exercise advice or ω-3 FA were 1.14(CI 0.35-3.67) and 0.67(CI 0.21-
2.18) (p=0.51), respectively. None of the adverse events were considered serious, with 
only one case of musculoskeletal pain possibly related to treatment resulting in 
cessation of exercise. The most frequently reported symptoms of diarrhoea (three 
cases) or epigastric discomfort (five cases)  were reported across all four patient groups 
(Figure 3). No patient discontinued the supplements due to adverse effects.  
DISCUSSION 
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This single site, pilot RCT tested the effect of advice to increase exercise, alone or in 
combination with ω-3 FA supplementation, on fatigue levels in inactive IBD. The 
interventions were shown to be generally well-tolerated, with only one possible 
treatment-related adverse event (musculoskeletal pain) resulting in discontinuation of 
the exercise intervention.  
This is the first study in IBD patients providing individually-prescribed advice relating to 
non-supervised PA on a Treat-to-Target basis[31], aiming to increase each individual 
participant’s PA by 30%. There was some indication that exercise advice improved IBD-
related fatigue. This was demonstrated by lower scores from the secondary outcome 
measure IBD-F – an IBD-fatigue specific scale - although this effect was not apparent 
from other fatigue scales, notably from the primary measure (FACIT-F scale). This raises 
the possibility that different scales detect different facets of fatigue (see Table II) - 
possibly occurring at varying frequencies in CD and UC patients - justifying further 
investigation. Advantages of the Treat-to-Target approach include promoting 
engagement in non-supervised exercise by previous non-exercisers: reports from 
participants receiving the exercise advice ranged from expressions of initial enthusiasm 
to life-changing positive experiences.  
Studies investigating the effect of exercise on symptoms of chronic disease including 
fatigue, have reported on similar intervention periods of 12 weeks or less [45, 46]. A 
recent RCT investigating the effect of a 10-week PA program in 30 cases of mild-
moderate IBD has reported a non-significant increase in HRQOL, predominantly 
through effects on the IBD-Q social subscale[21]. Thus, larger studies investigating the 
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effect of exercise on IBD-related fatigue, possibly including longer intervention periods,  
are warranted. 
In the ω-3 FA group, the finding of worsening of fatigue as measured by the FACIT-F 
scale was not statistically significant, and not observed with any of the other fatigue 
scales utilised; hence, results from this study do not provide evidence to support the 
effectiveness of ω-3 FA supplements on IBD-related fatigue. 
The effect of ω-3 FA on fatigue in IBD has not been studied previously. Results from 
RCTs in healthy individuals have shown varied effects of ω-3 FA supplementation (up 
to 12 weeks) on cognitive function and mood[37, 38, 47], and a  6-week intervention 
including ω-3 FA significantly reduced fatigue in patients with lung cancer[48]. 
However, in our study a 12-week period of ω-3 FA supplementation, did not appear 
sufficient to show a reduction in IBD-related fatigue.  
Previous studies using 1800mg-7000mg ω-3 FA per day (compared to the 2970mg daily 
dose in this study), showed positive effects on maintenance of IBD activity remission[1, 
49], although beneficial effects on IBD-related fatigue may require different dosage 
regimes. Omega-3 FA supplementation at lower dose (up to 690mg per day) and for a 
shorter period (8 weeks) than in the present study, significantly increased levels of 
blood erythrocyte ω-3 FAs [50], suggesting that the dosage and intervention period 
used in this study did produce biologically active levels of ω-3 FAs.  
Exercise has proven beneficial in healthy individuals[35]. Potential positive benefits 
were also reported in studies with IBD patients, including muscle mass gain[51], and 
increased bone mineral density and HRQOL[16]. Symptoms of IBD, such as diarrhoea, 
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especially if accompanied by fears of incontinence, may create barriers to exercise[52]. 
Evidence to date suggests that individuals with IBD should benefit from increased 
exercise[15, 22, 23, 53, 54], and in particular, that low-moderate intensity PA is safe[19, 
55]. The results from our study support these findings: no serious adverse effects 
related to exercise were reported. Clinicians’ reluctance to prescribe exercise because 
of the fear of symptom exacerbation can now be largely dispelled[16]. 
The strength of this study lies in its 2x2 factorial design; in the absence of interaction 
between the effects of exercise advice and ω-3 FA supplements on IBD-related fatigue, 
data from all participants could be analysed in two groups for each intervention (n=25-
27). The relatively small sample size may be seen as a limitation (and precluded 
comparison of CD and UC cases), although this can be justified given the trial’s pilot 
status.  The large numbers of patients excluded relates to the stringent eligibility 
criteria used to remove potential effects from confounding factors (e.g. fatigue-related 
comorbidities, 131/656;20%; pre-existing exercise or ω-3 FAs intake, 43/656; 7%), or 
else because of patients’ non-availability for the full study period (147/656;23%).  
Whilst the self-report diaries used in this study may be useful tools to confirm 
adherence to protocols, they have known limitations since their veracity cannot be 
proven. However, careful review of the completed diaries suggested contemporaneous 
completion without systemic bias regarding nutritional intake. 
Conclusions 
This was the first study assessing the effect of exercise advice and/or ω-3 FA 
supplementation in IBD patients with inactive disease: the results demonstrate that 
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these interventions are generally well-tolerated, and suggest that patients with IBD-
related fatigue could safely increase levels of PA. There is a need for further 
investigation in a larger sample to derive recommendations and specific practice-based 
guidelines; in addition, the use of IBD-F, a population-specific disease scale, should be 
considered in future studies. Omega-3 FA supplementation did not produce positive 
results on IBD-related fatigue, although there were no serious adverse effects related 
to its intake. It is possible that regular PA may provide an effective self-management 
option in IBD-related fatigue.  
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TABLES 
 
       Exercise Advice     
  Yes  No  
Omega-3 Fatty 
Acids 
Yes Exercise advice +   
ω-3 FAs (Group 1) 
ω-3 FAs  
(Group 3) 
 
No Exercise advice 
(Group 2) 
Neither  
(Group 4) 
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Treatment Groups: 
1) Exercise advice with ω-3 FAs supplement capsule (n=11):  
Consultation with personal trainer; activity and diet diary; omega-3 fatty acid 
capusles 
2) Exercise advice with placebo capsule (n=15):  
Consultation with personal trainer; activity and diet diary; placebo capsule 
3) ω-3 FA supplement capsule with exercise placebo (n=14) 
Consultation with researcher; diet diary; omega-3 fatty acid capusles  
4) Placebo capsule with exercise placebo (n=12) 
Consultation with researcher; diet diary; placebo capsule 
 
Table I: 2x2 Trial Design and Details of Treatment Groups.   
 
ω-3 FAs: Omega-3 Fatty Acids. 
 
 
 
 
 
 
 
Outcome variable Scale/Assessment Outcome Rationale 
Fatigue score Functional 
Assessment of 
Chronic Illness 
Therapy – Fatigue 
scale[39] 
Primary  The only fatigue scale 
validated  in IBD 
patients at the time of 
the study design  
Fatigue score Multiple Fatigue 
Inventory 
scale[40] 
Secondary  
 
 
 
The most frequently-
used scale in studies 
of IBD fatigue (but not 
validated in the IBD 
population) 
Fatigue score Inflammatory 
Bowel Disease- 
Fatigue scale[41] 
Secondary  Scale developed and 
tested in the IBD 
population; used in 
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this study to further 
test its validity 
Quality of Life 
score 
Inflammatory 
Bowel Disease – 
Quality of Life 
scale[42] 
Secondary  Health-related quality 
of life scale validated 
for use with IBD 
patients 
Depression score Hospital Anxiety 
and Depression 
scale[43] 
Secondary Scale assessing role of 
anxiety and 
depression in 
influencing fatigue 
levels 
Activity counts  
per minute; Time 
spent in 
Moderate-
Vigorous Physical 
Activity;  
Daily steps 
Accelerometer, 
GT1M 
(Actigraph)[44] 
Secondary  Objective measure of 
physical activity 
Disease activity 
score 
Harvey-Bradshaw 
Index[33]  and 
Simple Clinical 
Colitis Index[34] 
Secondary Validated scales 
indicating level of 
disease activity  
Height and weight 
measurement 
Procedure Secondary To indicate change in 
body composition 
Haemoglobin 
measurement 
Procedure - blood 
test 
Secondary To determine iron 
status 
C-Reactive Protein 
measurement 
Procedure  - 
blood test 
Secondary As a marker of 
inflammation 
 
Table II: Details of Assessment Tools Used for Data Collection. 
IBD: Inflammatory bowel disease 
 
 
Variable Placebo Omega-3 Fish Oils p-value 
 No Exercise 
(n=12) 
Exercise 
(n=15) 
No Exercise 
(n=14) 
Exercise 
(n=11) 
 
      
Age a 31 (27, 51) 35 (28, 43) 45 (36, 51) 31 (29, 55) 0.52 
      
Gender - Male 4 (33%) 8 (53%) 7 (50%) 6 (55%) 0.74 
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Ethnicity - White 9 (75%) 10 (67%) 14 (100%) 9 (82%) 0.11 
                 - Other 3 (25%) 5 (33%) 0 (0%) 2 (18%)  
      
Smoker - No 11 (92%) 14 (93%) 13 (93%) 9 (82%) 0.80 
      
Haemoglobin b 13.7 (1.7) 13.6 (1.4) 13.5 (0.9) 13.8 (1.4) 0.96 
      
CRP a 1.6 (0.7, 2.7) 1.0 (0.6, 3.3) 1.2 (0.7, 3.2) 2.4 (1.2, 6.2) 0.29 
      
BMI (kg/m2) b 24.9 (4.5) 23.9 (4.2) 25.7 (3.9) 26.3 (3.1) 0.46 
 
Diagnosis - CD 
 
6 (50%) 
 
6 (40%) 
 
7 (50%) 
 
6 (55%) 
 
0.99 
   - UC 6 (50%) 8 (53%) 7 (50%) 5 (45%)  
   - IBD 
unclassified  
0 (0%) 1 (7%) 0 (0%) 0 (0%)  
      
Surgery 3 (25%) 5 (33%) 5 (36%) 3 (27%) 0.93 
      
 Stoma 0 (0%) 1 (7%) 2 (14%) 0 (0%) 0.54 
      
SCCI c 5.0 (2.9) 5.6 (1.7) 4.9 (0.9) 5.0 (2.2) 0.90 
      
HBI d 4.8 (2.7) 4.9 (3.1) 6.0 (2.8) 5.3 (4.3) 0.90 
 
Table III: Demographics and Baseline Variables of the Study Participants. 
 a Median (inter-quartile range) reported. b Mean (standard deviation) reported. c Figures for 
patients with ulcerative colitis and unclassified inflammatory bowel disease. d Figures for 
patients with Crohn's disease and unclassified inflammatory bowel disease. P-value ≤0.01 
indicates a statistically significant difference between the four groups. CRP: C - reactive protein; 
 
 
25 
 
BMI: Body Mass Index; CD: Crohn’s disease; UC: Ulcerative Colitis; IBD: Inflammatory Bowel 
Disease; SCCI: Simple Clinical Colitis Index; HBI: Harvey Bradshaw Index. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Interaction 
e 
Exercise Advice (n=26) Omega-3 Fish Oils (n=25) 
 p-value Mean (95% CI) p-value Mean (95% CI) p-value 
FACIT-F 0.24 1.8 (-2.3, 5.8) 0.38 -4.6 (-8.6, -0.7) 0.02  
      
 
 
26 
 
SCCI a 0.13 -0.6 (-1.8, 0.7) 0.37 -0.4 (-1.6, 0.9) 0.54 
HBI b 0.77 -2.0 (-4.2, 0.2) 0.07 1.1 (-1.1, 3.3) 0.31 
      
≥ 1 day’s 
capsules missed 
c 
0.30 0.70 (0.17, 2.96) 0.63 2.17 (0.52, 9.00) 0.29 
      
Mean 
MVPA/day 
0.80 -7.5 (-22.6, 7.6) 0.32 -9.9 (-25.1, 5.3) 0.20 
CPM 0.78 57 (-153, 39) 0.24 -46 (-142, 51) 0.35 
Steps/day 0.71 -443 (-2829, 
1942) 
0.71 -1212 (-3600, 
1176) 
0.31 
Wear time/day 0.14 -0.8 (-3.1, 1.4) 0.46 0.0 (-2.3, 2.3) 0.97 
Calendar days 0.47 -0.8 (-2.0, 0.4) 0.17 -0.2 (-1.4, 0.9) 0.71 
      
Hemoglobin 0.04  -0.1 (-0.5, 0.3) 0.63 0.0 (-0.4, 0.4) 0.93 
CRP d 0.47 0.76 (0.48, 1.20) 0.24 0.95 (0.59, 1.51) 0.81 
Weight (kg) 0.76 0.3 (-1.1, 1.7) 0.69 -0.3 (-1.8, 1.1) 0.64 
      
IBD-F Section I 0.48 -2.0 (-3.8, -0.2) 0.03  0.7 (-1.1, 2.5) 0.42 
IBD-F Section II 0.33 -3.8 (-10.4, 2.7) 0.25 6.0 (-0.4, 12.3) 0.07 
      
MFI general 0.53 -1.5 (-3.1, 0.1) 0.07 0.1 (-1.5, 1.7) 0.92 
MFI physical 0.50 -0.9 (-2.6, 0.8) 0.30 1.1 (-0.5, 2.8) 0.18 
MFI activity 0.70 -0.7 (-2.6, 1.3) 0.50 1.1 (-0.8, 3.0) 0.26 
MFI motivation 0.35 -0.9 (-2.6, 0.8) 0.30 0.9 (-0.8, 2.6) 0.30 
MFI mental 0.27 -0.60 (-2.4, 1.2) 0.50 -0.38 (-2.2, 1.4) 0.67 
      
IBD-Q 0.83 3 (-7, 14) 0.56 2 (-9, 12) 0.74 
      
HADS Anxiety 0.29 0.0 (-1.5, 1.6) 0.97 0.9 (-0.6, 2.4) 0.23 
HADS 
Depression 
0.55 0.1 (-1.3, 1.5) 0.86 1.0 (-0.4, 2.4) 0.16 
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Table IV: Comparisons of the effects of exercise advice and fish oil capsules compared with 
no exercise advice and placebo capsules respectively, on physical activity and fatigue 
assessments in patients with Inflammatory Bowel Disease.  
a Figures for patients with UC and unclassified IBD; b Figures for patients with Crohn's disease 
and unclassified inflammatory bowel disease; c Odds Ratio (95% CI) reported; d Variable 
analyzed on log scale. Ratio (95% CI) reported;  e  Indicates whether the effects of exercise 
advice are independent from those of omega-3 fish oils.  For all outcomes, p≤0.01 indicates a 
statistically significant difference between groups.  Differences were adjusted for baseline 
differences between groups.  FACIT-F: Functional Assessment of Chronic Illness Therapy – 
Fatigue scale; SCCI: Simple Clinical Colitis Index; HBI: Harvey Bradshaw Index; MVPA: Moderate-
vigorous physical activity; CPM: Counts per minute; CRP: C - reactive protein; IBD-F: 
Inflammatory Bowel Disease-Fatigue scale; MFI: Multidimensional Fatigue Inventory scale; IBD-
Q: Inflammatory Bowel Disease – Quality of Life scale; HADS: Hospital Anxiety and Depression 
Scale. 
 
 
 
 
 
 
 
FIGURES LEGENDS 
 
Figure 1: Study Outline and Schedule 
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FACIT-F: Functional Assessment of Chronic Illness Therapy - Fatigue scale; IBD-F: Inflammatory 
Bowel Disease - Fatigue scale; MFI: Multidimensional Fatigue Inventory scale; IBD-Q: 
Inflammatory Bowel Disease - Quality of Life scale; HADS: Hospital Anxiety and Depression 
Scale. 
Figure 2: CONSORT Flowchart for Patients in Inflammatory Bowel Disease and Fatigue Study 
Figure 3: Adverse Effects Reported during 12-week Intervention of Advice to Increase Physical 
Activity and/or Omega-3 Fatty Acids.  IBD: inflammatory bowel disease. 
 
 
 
